Atai Life Sciences announces $50M private placement

Atai Life Sciences (ATAI) announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary shares of atai with a nominal value of EUR 0.10 per share and pre-funded warrant to purchase 4,566,210 Common Shares. The financing is expected to result in gross proceeds of approximately $50M, before deducting placement agents’ fees and other expenses. The net proceeds from the financing are expected to be used by atai for general corporate purposes, including for working capital and to advance the clinical development of the company’s product candidates and programs. The private placement is subject to certain closing conditions, including the expiration of the waiting period pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 related to the filing expected to be made by Christian Angermayer in connection with Apeiron’s investment in this financing. The financing is expected to close in the third quarter of 2025. TD Cowen, Leerink Partners, Guggenheim Securities and Berenberg are acting as joint-lead placement agents for the private placement.